Prognostic impact of p63 and p53 expression in upper urinary tract transitional cell carcinoma

Hall, 1998, Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract, Urology, 52, 594, 10.1016/S0090-4295(98)00295-7 Ooms, 1983, Analysis of the performance of pathologists in the grading of bladder tumors, Hum Pathol, 114, 140, 10.1016/S0046-8177(83)80242-1 Di Como, 2002, p63 expression profiles in human normal and tumor tissues, Clin Cancer Res, 8, 494 Yang, 1998, p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities, Mol Cell, 2, 305, 10.1016/S1097-2765(00)80275-0 Yang, 1999, p63 is essential for regenerative proliferation in limb, craniofacial, and epithelial development, Nature, 398, 714, 10.1038/19539 Urist, 2002, Loss of p63 expression is associated with tumor progression in bladder cancer, Am J Pathol, 161, 1199, 10.1016/S0002-9440(10)64396-9 Pelosi, 2002, p63 immunoreactivity in lung cancer, J Pathol, 198, 100, 10.1002/path.1166 Hagiwara, 1999, Mutational analysis of the p63/p73L/p51/p40/CUSP/KET gene in human cancer cell lines using intronic primers, Cancer Res, 59, 4165 Park, 2000, Frequent alteration of p63 expression in human primary bladder carcinomas, Cancer Res, 60, 3370 Koga, 2003, Impaired DeltaNp63 expression associates with reduced beta-catenin, Br J Cancer, 88, 740, 10.1038/sj.bjc.6600764 Levine, 1991, The p53 tumour suppressor gene, Nature, 351, 453, 10.1038/351453a0 Nakanishi, 1996, Immunohistochemical evaluation of p53 oncoprotein in transitional cell carcinoma of the upper urinary tract, Hum Pathol, 27, 1336, 10.1016/S0046-8177(96)90347-0 Rey, 1997, Overexpression of p53 in transitional cell carcinoma of the renal pelvis and ureter, Cancer, 79, 2178, 10.1002/(SICI)1097-0142(19970601)79:11<2178::AID-CNCR16>3.0.CO;2-T 2002 1998 Kononen, 1998, Tissue microarrays for high-throughput molecular profiling of tumor specimens, Nat Med, 4, 844, 10.1038/nm0798-844 Bernardini, 1999, Immunohistochemical detection of p53 protein overexpression versus gene sequencing in urinary bladder carcinomas, J Urol, 162, 1496, 10.1016/S0022-5347(05)68347-4 Tiguert, 2001, Structural alteration of p53 protein in patients with muscle invasive bladder transitional cell carcinoma, J Urol, 166, 2155, 10.1016/S0022-5347(05)65525-5 Bernardini, 2001, The predictive value of muscularis mucosae invasion and p53 over expression on progression of stage T1 bladder carcinoma, J Urol, 165, 42, 10.1097/00005392-200101000-00011 Shiina, 1996, Immunohistochemistry of p53 protein in transitional-cell carcinoma of the bladder using an image analyzer, Oncology, 53, 233, 10.1159/000227566 Shiina, 1999, Clinical significance of mdm2 and p53 expression in bladder cancer, Oncology, 56, 239, 10.1159/000011971 Fleshner, 2000, p53 nuclear accumulation is not associated with decreased disease-free survival in patients with node positive transitional cell carcinoma of the bladder, J Urol, 164, 1177, 10.1016/S0022-5347(05)67136-4